Wirkstoffe & Arzneimittelsicherheit

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (22)

Wechselwirkungen · DaTSCAN

DaTSCAN 74 MBq/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5

HOS-090541 · Präparat HOS-084079

Ioflupane binds to the dopamine transporter. Medicines that bind to the dopamine transporter with high affinity may therefore interfere with DaTSCAN diagnosis. These include amfetamine, bupropion, cocaine, codeine, dexamfetamine, methylphenidate, modafinil, and phentermine. Selective serotonin reuptake inhibitors (SSRIs), such as sertraline, may increase or decrease ioflupane binding to the dopamine transporter. Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, may decrease ioflupane binding to the dopamine transporter especially in patients on higher doses.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ioflupane (HOS-090542) norepinephrine (HOS-090547) bupropion (HOS-086329) codeine (HOS-090544) modafinil (HOS-090546) dopamine (HOS-085948) methylphenidate (HOS-090545) venlafaxine (HOS-086573) cocaine (HOS-090543) phentermine (HOS-087483) serotonin (HOS-085477) sertraline (HOS-086247)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-25T02:00:00Z · SHA-256 f40f7ad424fba21e279058645a7f9123ad356bfb210f5e9a98e718256e3987ab · Passage b61bee0e5f8e9e99224bcb5a4db13e8cfb7d2e33ddbe5e161cf3103ca90bf479 · Zeichen 55–644 im Abschnitt

Wechselwirkungen · Azilect

AZILECT 1 mg tablets · Abschnitt 4.5 · PDF-Seite 4

HOS-113316 · Präparat HOS-093909

For concomitant use of rasagiline with selective serotonin reuptake inhibitors (SSRIs)/selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in clinical trials, see section 4.8.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-04-08T15:00:00Z · SHA-256 5aca218191417820622c35e4d3518e059be3e9d90752c7aded0ac355eb0d2e23 · Passage b31513c170fa21871bd499474e9769eff8cdb67a71a67278c130eef130cce44b · Zeichen 1455–1641 im Abschnitt

Wechselwirkungen · Suboxone

Suboxone 2 mg/0.5 mg sublingual tablets Suboxone 8 mg/2 mg sublingual tablets Suboxone 16 mg/4 mg sublingual tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-115848 · Präparat HOS-094369

• Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitor (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-25T15:36:00Z · SHA-256 53df145bc12212064132de2f19d68d1c0074d2217b26658d050ac86495c25fa2 · Passage 00bb88491f228b39e18840f98d930922b8804c0e51b1b01f5346b6f8c9bd8986 · Zeichen 2031–2346 im Abschnitt

Wechselwirkungen · Suboxone

Suboxone 2 mg/0.5 mg sublingual film Suboxone 4 mg/1 mg sublingual film Suboxone 8 mg/2 mg sublingual film Suboxone 12 mg/3 mg sublingual film · Abschnitt 4.5 · PDF-Seite 26

HOS-115876 · Präparat HOS-094369

• Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitor (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Pradaxa

Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14

HOS-118660 · Präparat HOS-094855

Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 4500fbb1421be734520861bad41a7291e03a16a6b9632885a341d674dc8f2e68 · Zeichen 11431–11547 im Abschnitt

Wechselwirkungen · Pradaxa

Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 47

HOS-118732 · Präparat HOS-094855

Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Pradaxa

Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 87

HOS-118821 · Präparat HOS-094855

Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Pradaxa

Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 121

HOS-118907 · Präparat HOS-094855

Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Effentora

Effentora 100 micrograms buccal tablets Effentora 200 micrograms buccal tablets Effentora 400 micrograms buccal tablets Effentora 600 micrograms buccal tablets Effentora 800 micrograms buccal tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-209220 · Präparat HOS-154273

Serotoninergic agents Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition. Effentora is not recommended for use in patients who have received MAOIs within 14 days because severe and unpredictable potentiation by MAOIs has been reported with opioid analgesics.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-19T10:58:00Z · SHA-256 b4a304bd9d2ca3f423d95be522ff20307f46a2ce762379e94c21a56805a240f8 · Passage 1585dba6923b023b097416350e62c87fc13e537cf7ba5656383bf2bd9e92aea2 · Zeichen 2328–2835 im Abschnitt

Wechselwirkungen · Instanyl

Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7

HOS-120556 · Präparat HOS-095157

Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage bad3795141e723888d2a1125a94e0c124a847288d1c71d06c5d8caa5f0790e4a · Zeichen 116–415 im Abschnitt

Wechselwirkungen · Instanyl

Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20

HOS-120581 · Präparat HOS-095157

Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Instanyl

Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 33

HOS-120604 · Präparat HOS-095157

Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · PecFent

PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution · Abschnitt 4.5 · PDF-Seite 8

HOS-212299 · Präparat HOS-154864

Serotoninergic medicinal products: Coadministration of fentanyl with a serotoninergic medicinal product, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T09:30:00Z · SHA-256 6c66e20c8a5497199e4a93d57ee169d120fab4ca07ded4b5af9add0ded3852e4 · Passage 0d58cbdc6c39acfd13b1ac70fd25b33598ad58fe389df70f069271d48ca0ec89 · Zeichen 1965–2311 im Abschnitt

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16

HOS-215304 · Präparat HOS-155418

Efavirenz: AUC: ↔ Cmax: ↑ 11% (↑ 6 to ↑ 16) Cmin: ↔ (CYP3A4 induction) Paroxetine/efavirenz No clinically significant No dose adjustment is necessary (20 mg once daily/600 mg once pharmacokinetic interaction for either medicinal product. daily) Fluoxetine/efavirenz Interaction not studied. Since No dose adjustment is necessary fluoxetine shares a similar metabolic for either medicinal product. profile with paroxetine, i.e. a strong CYP2D6 inhibitory effect, a similar lack of interaction would be expected for fluoxetine. Norepinephrine and dopamine reuptake inhibitor Bupropion/efavirenz Bupropion: Increases in bupropion dosage [150 mg single dose (sustained AUC: ↓ 55% (↓ 48 to ↓ 62) should be guided by clinical release)/600 mg once daily] Cmax: ↓ 34% (↓ 21 to ↓ 47) response, but the maximum recommended dose of bupropion Hydroxybupropion: should not be exceeded. No dose AUC: ↔ adjustment is necessary for Cmax: ↑ 50% (↑ 20 to ↑ 80) efavirenz. (CYP2B6 induction) ANTIHISTAMINES Cetirizine/efavirenz Cetirizine: No dose adjustment is necessary (10 mg single dose/600 mg once AUC: ↔ for either medicinal product. daily) Cmax: ↓ 24% (↓ 18 to ↓ 30) These changes are not considered clinically significant.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) norepinephrine (HOS-090547) bupropion (HOS-086329) dopamine (HOS-085948) fluoxetine (HOS-085946) cetirizine (HOS-215305)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage f6abe2540d545b6a7b0c3b11a7d04068ce9f1e9463270db973d45e56e0d79fa2 · Zeichen 45029–47167 im Abschnitt

Wechselwirkungen · Xadago

Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5

HOS-125739 · Präparat HOS-096139

4 Serious adverse reactions have been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic/tetracyclic antidepressants and MAO inhibitors (see section 4.4). In view of the selective and reversible MAO-B inhibitory activity of safinamide, antidepressants may be administered but used at the lowest doses necessary.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage b79f8d740563d58e8e70a9e0d21a8597812e0c8ddd235c2febd314c425dd97ff · Zeichen 1947–2358 im Abschnitt

Wechselwirkungen · Latuda

Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6

HOS-128657 · Präparat HOS-096607

5 Latuda should be used cautiously when co-administered with other serotonergic agents, such as buprenorphine/opioids, MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) buprenorphine (HOS-086193) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage 70c3f5fb66e37b06683588c4d4e5694ba7fdc260389391cf815875e0918ca96a · Zeichen 575–952 im Abschnitt

Wechselwirkungen · Mysimba

Mysimba 8 mg/90 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-130325 · Präparat HOS-096899

There have been post-marketing reports of serotonin syndrome, a potentially life-threatening condition, when naltrexone/bupropion was co-administered with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs) and opioids (e.g. tramadol, methadone) (see sections 4.4 and 4.8).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) methadone (HOS-086198) serotonin (HOS-085477) tramadol (HOS-112871)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-07T14:58:00Z · SHA-256 8d91203fd1313606105ccfcfeb588970833594eb1edb4edb571e8c8ed61c515c · Passage 8e7981b179b606d8fed114d475988d78ae74d7f969a5f6d80a9c0043800d70ab · Zeichen 2540–2894 im Abschnitt

Wechselwirkungen · Dzuveo

Dzuveo 30 micrograms sublingual tablet · Abschnitt 4.5 · PDF-Seite 5

HOS-137933 · Präparat HOS-098113

Co-administration of sufentanil with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), or Monoamine Oxidase Inhibitors (MAOIs), may increase the risk of serotonin syndrome, a potentially life threatening condition. Monoamine Oxidase Inhibitors must not be taken in the 2 weeks before or at the same time as Dzuveo is given.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-04T09:41:00Z · SHA-256 11a627f517ef165f1c214a9467017376a3e2707d6037112cbc10731d39d973c1 · Passage 362400cc2eed0f3596c494ae51f36bfc8ef6c06f759c062950aff04f44c8b2b7 · Zeichen 1882–2288 im Abschnitt

Wechselwirkungen · Zubsolv

Zubsolv 0.7 mg/0.18 mg sublingual tablets Zubsolv 1.4 mg/0.36 mg sublingual tablets Zubsolv 2.9 mg/0.71 mg sublingual tablets Zubsolv 5.7 mg/1.4 mg sublingual tablets Zubsolv 8.6 mg/2.1 mg sublingual tablets Zubsolv 11.4 mg/2.9 mg sublingual tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-138581 · Präparat HOS-098216

Zubsolv should be used cautiously when co-administered with: • Sedatives such as benzodiazepines or related medicinal products The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use of sedative medicinal products should be limited (see section 4.4). Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking this medicinal product and should also be cautioned to use benzodiazepines concurrently with this medicinal product only as directed by their physician (see section 4.4). • The concomitant use of Zubsolv with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death (see section 4.4). • Other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression. The reduced level of alertness can make driving and using machines hazardous. • Furthermore, adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine/naloxone. Therefore the potential to overdose with a full agonist exists, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining • Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4) • naltrexone and nalmefene are opioid antagonists that can block the pharmacological effects of buprenorphine. Co-administration during buprenorphine/naloxone treatment is 9 contraindicated due to the potentially dangerous interaction that may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms (see section 4.3). • CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine Patients receiving Zubsolv should be closely monitored, and may require dose-reduction if combined with potent CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir or azole antifungals such as ketoconazole or itraconazole, macrolide antibiotics). • CYP3A4 inducers: Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in sub-optimal treatment of opioid dependence with buprenorphine. It is recommended that patients receiving buprenorphine/naloxone should be closely monitored if inducers (e.g. phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered. The dose of buprenorphine or the CYP3A4 inducer may need to be adjusted accordingly. • The concomitant use of monoamine oxidase inhibitors (MAOI) might produce exaggeration of the effects of opioids, based on experience with morphine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) pregabalin (HOS-112893) norepinephrine (HOS-090547) nelfinavir (HOS-084520) methadone (HOS-086198) protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) clonidine (HOS-088594) carbamazepine (HOS-085618) naltrexone (HOS-115836) nalmefene (HOS-115837) morphine (HOS-086053) gabapentin (HOS-090745) serotonin (HOS-085477) itraconazole (HOS-084516) ritonavir (HOS-084521) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-08T09:49:00Z · SHA-256 5abf2fbb0a7fd36ed1be04f576c9d6b4a021a25a707c692fa21b326376a4f2b5 · Passage 36507a34d513c06aeda586e977de80135455da379f00364e466d3a649d3e2c11 · Zeichen 232–4044 im Abschnitt

Wechselwirkungen · Buvidal

Buvidal 8 mg prolonged-release solution for injection Buvidal 16 mg prolonged-release solution for injection Buvidal 24 mg prolonged-release solution for injection Buvidal 32 mg prolonged-release solution for injection · Abschnitt 4.5 · PDF-Seite 8

HOS-140298 · Präparat HOS-098498

Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioid antagonists that can block the pharmacological effects of buprenorphine. For opioid-dependent patients currently receiving buprenorphine treatment, naltrexone may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms. For patients currently receiving naltrexone treatment, the intended therapeutic effects of buprenorphine administration may be blocked by naltrexone. • alcoholic drinks or medicinal products containing alcohol as alcohol increases the sedative effect of buprenorphine (see section 4.7). • benzodiazepines: This combination may result in death due to respiratory depression of central origin. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines whilst taking this product, and should also be cautioned to use benzodiazepines concurrently with this product only as directed by their physician (see section 4.4). • gabapentinoids: The concomitant use of Buvidal with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death. Therefore, dosages must be closely monitored and this combination must be avoided in cases where there is a risk of misuse. Patients should be cautioned to use gabapentinoids concurrently with this product only as directed by their physician (see section 4.4). • Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4). • other central nervous system depressants: Other opioid derivatives (e.g. methadone, analgesics and antitussives); certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, antipsychotics, clonidine and related substances. These combinations increase central nervous system depression. The reduced level of alertness can make driving and using machinery hazardous (see section 4.7). • opioid analgesics: Adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving buprenorphine. The potential for overdose also exists with a full agonist, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining (see section 4.4) • Buprenorphine is metabolised to norbuprenorphine primarily by CYP3A4. Interaction with co- administered inducers or inhibitors have been established in studies using transmucosal and transdermal buprenorphine. Buprenorphine is also metabolised to buprenorphine-3β- glucuronide by UGT1A1. • CYP3A4 inhibitors may inhibit the metabolism of buprenorphine resulting in increased Cmax and AUC of buprenorphine and norbuprenorphine. Buvidal avoids first-pass effects and CYP3A4 inhibitors (e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, or azole antifungals such as ketoconazole or itraconazole, or macrolide antibiotics) are

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) pregabalin (HOS-112893) norepinephrine (HOS-090547) nelfinavir (HOS-084520) methadone (HOS-086198) protease (HOS-085623) ketoconazole (HOS-084513) clonidine (HOS-088594) naltrexone (HOS-115836) nalmefene (HOS-115837) gabapentin (HOS-090745) serotonin (HOS-085477) itraconazole (HOS-084516) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-21T17:42:00Z · SHA-256 1ad9ce13109b545d01c45ffd56cec5dc90c2b7294f4e2ae1f7e5e985c1a064eb · Passage 2507cd2f2663aa4a74d791faab2504c7371d895671fa1111e3aab02507c0c573 · Zeichen 58–3582 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.